871826-47-0 Usage
Uses
Used in Pharmaceutical Industry:
10(S),17(S)-DiHDoHE is used as an anti-inflammatory and pro-resolving agent for its potent properties in resolving inflammation and promoting tissue repair. It modulates immune response and has potential therapeutic applications in inflammation-related diseases.
Used in Cardiovascular Health:
10(S),17(S)-DiHDoHE is used as a cardiovascular health promoter for its beneficial effects on cardiovascular function, potentially reducing the risk of cardiovascular diseases.
Used in Neurological Function:
10(S),17(S)-DiHDoHE is used as a neurological function enhancer for its positive impact on brain health and cognitive function, potentially improving neurological outcomes in various conditions.
Used in Drug Development:
10(S),17(S)-DiHDoHE is used as a target for the development of novel therapeutics for inflammation-related diseases, given its promising properties in regulating immune response and promoting tissue regeneration.
Check Digit Verification of cas no
The CAS Registry Mumber 871826-47-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,8,2 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 871826-47:
(8*8)+(7*7)+(6*1)+(5*8)+(4*2)+(3*6)+(2*4)+(1*7)=200
200 % 10 = 0
So 871826-47-0 is a valid CAS Registry Number.
871826-47-0Relevant articles and documents
TOTAL SYNTHESES OF SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS), STRUCTURAL ISOMERS AND STRUCTURAL ANALOGS
-
Paragraph 00173, (2022/02/09)
A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I): (I) wherein R1 is alkyl(C≤12), cycloalkyl(C≤12), alkenyl(C≤12), alkylidene(C≤12), alkynyl(C≤12), aryl, aralkyl, heteroaryl or heteroaralkyl; and X1, X2 and X3 are each independently hydroxy or OP, wherein P is a hydroxy protecting or hydroxy activating group; with a reducing agent under conditions sufficient to produce a compound of the formula (II): (II) wherein: R1, X1, X2 and X3 are as defined above. Novel protectins, more specifically novel structural isomers and analogs of PD1 and PDX are also disclosed.
Total Synthesis of the Antidiabetic (Type 2) Lipid Mediator Protectin DX/PDX
Sancéau, Jean-Yves,Maltais, René,Poirier, Donald,Marette, André
, p. 495 - 505 (2019/01/24)
The first total synthesis of a lipid mediator derived from natural ?-3-fatty acid docosahexaenoic acid (DHA), 10S,17S-diHDHA (also referred to as protectin DX/PDX), was achieved in a convergent route (29 steps). The two chiral hydroxyl groups at C-10 and
